Dosing and Sequencing Bispecifics and CAR T-Cell Therapies in R/R MM
Key opinion leaders share comprehensive insight on optimal dosing and sequencing strategies in patients with relapsed/refractory multiple myeloma.
RRMM: Access to Bispecifics and CAR T-Cell Therapy in Satellite Campuses
A brief conversation on the introduction and use of bispecifics and CAR T-cell therapies in satellite campuses for patients with relapsed/refractory multiple myeloma.
Expanding the Treatment Armamentarium in RRMM with Novel Therapies
Switching focus to the relapsed/refractory setting, panelists reflect on the treatment armamentarium available to patients with multiple myeloma at early relapse.
Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma
Key opinion leaders in multiple myeloma consider duration of therapy and the possibility of treatment discontinuation for newly diagnosed patients.
Treatment Paradigm for Patients With Transplant Ineligible NDMM
Centering discussion on transplant ineligible multiple myeloma, expert panelists review mainstay treatment regimens and strategies in the first-line setting.
Treatment of MM: Value of Tumor Boards in Practice
Shared insight on the respective value of consolidation therapy and collaborative tumor boards when managing patients with transplant-eligible multiple myeloma.
Role of Transplant in Newly Diagnosed Multiple Myeloma
A brief overview of stem cell transplant’s role in the first-line treatment setting of newly diagnosed multiple myeloma.
Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma
Expert panelists review available induction therapy regimens for patients newly diagnosed with transplant-eligible multiple myeloma in the context of clinical data.
2 Clarke Drive Cranbury, NJ 08512